Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 in Participants Living With Overweight or Obesity
NCT07395687Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of UBT251 in obesity (11 arms), sponsored by Novo Nordisk. Primary endpoints: Number of treatment emergent adverse events at 43 days, Relative change in body weight at 28 weeks and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
UBT251
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07395687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395687.